Fagron Genomics

Name

Fagron Genomics

Legal name

Fagron Genomics S.L.U.

Website

https://fagrongenomics.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Genetic Diagnostic Testing Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

akta.pro secondary industries

Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Genomic Profiling & Sequencing-Based Precision Medicine (HLAAANAA), Genetic & Prenatal Testing Laboratories (HLAFAMAH)

Keywords

• Pharmacogenetic testing
• Personalized genomic medicine
• Nutrigenomic testing services
• Dermatology genetic diagnostics
• DNA-based treatment algorithms

Headquarters

HQ city

Terrassa

HQ country

Spain

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain

Revenue model

1. Genetic Testing Kits and Analysis: Fagron Genomics provides DNA collection kits to healthcare professionals, processes samples in their laboratory, and delivers personalized genetic reports with treatment recommendations. Revenue is generated per test sold to physicians/clinics. The company also offers personalized magistral formulations recommended by the test results.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Fagron Genomics develops and sells DNA-based genetic tests (NutriGen, TrichoTest™, TeloTest, AcneTest, Sport Test) that combine buccal-swab DNA analysis with patient anamnesis using proprietary medical genetic algorithms to produce personalized prescriptions specifying active pharmaceutical ingredients and dosages for healthcare professionals in dermatology, trichology, aesthetics, and nutrition. The 360-degree solution spans DNA collection kit supply, laboratory sample processing, genetic interpretation, personalized treatment recommendations, and ongoing clinical genetic counselling, supported by CE-marked IVD medical device software and ISO 13485:2016 certification.

Product overview

Fagron Genomics is a genetic testing company offering a portfolio of five core genetic tests (NutriGen, TrichoTest™, TeloTest, AcneTest, and Sport Test) designed to deliver personalized, science-based treatment recommendations for physicians in Aesthetics, Dermatology, Trichology, and Nutrition. The company provides a 360° solution encompassing DNA sample collection kit supply, genetic analysis using proprietary medical algorithms, personalized treatment formulas with suitable active ingredients and doses (oral, topical, injectable/mesotherapy), and clinical genetic counseling. Each test uses distinct algorithms analyzing genetic polymorphisms combined with patient history to generate personalized reports and prescriptions. The company also offers TrichoConcept™, a complementary line of compounding vehicles for alopecia treatment. Services are delivered through a secure online platform accessible to healthcare professionals and patients.

Differentiator

Problem solved

Functional benefit

Brands

• NutriGen: Innovative nutrigenomic algorithm to personalize optimal diet and/or weight loss plans based on genetic analysis.
• TrichoTest
• TeloTest
• AcneTest
• Sport Test
• TrichoConcept

Products and services

• NutriGen Nutrigenomic genetic test analyzing 100+ genetic variations across 15 macrocategories (morphological genetics, behavioral genetics, flavor sensitivities, fat/lipid/carbohydrate/glucose metabolism, exercise efficacy, detoxification, hormones, inflammation, diet effectiveness) combined with patient health and behavioral information to generate personalized diet plans, weight loss programs, and supplement recommendations for healthcare professionals treating patients with nutrition and weight management needs.
• TrichoTest™ Pharmacogenetic test analyzing 26 single-nucleotide polymorphisms (SNPs) across 9 categories (prostaglandins, anti-inflammatories, anti-androgens, circulation, collagen synthesis, IGF, vitamins, minerals, antioxidants) combined with patient anamnesis to personalize alopecia treatment (androgenetic alopecia, alopecia areata, telogen effluvium) in adult males and females, selecting from 11 vehicles and 62 active pharmaceutical ingredients for physicians and trichologists.
• TeloTest Automated telomere length test that measures telomere length, determines biological/cellular age, and combines results with clinical history to recommend personalized anti-aging formulas and lifestyle/nutrition guidance, delivered to physicians and patients via secure online platform within 2 weeks of sample receipt.
• AcneTest Genetic test that analyzes patient-specific metabolic characteristics and genetic factors to generate personalized acne treatment prescriptions for dermatologists and aesthetic physicians.
• Sport Test Genetic test that uses DNA analysis to tailor athletic training and recovery plans, enhance endurance, and minimize injury risks; can be combined with NutriGen to optimize diet and supplementation for athletes and active patients under physician guidance.
• TrichoConcept™ Line of compounding vehicles compatible with Active Pharmaceutical Ingredients (APIs) and Dermaceutical Ingredients (DCIs) used to treat alopecia, featuring the patented TrichoTech phytocomplex of carefully chosen essential oils that act synergistically on the scalp.

Quantifiable outcome

• Over 250,000 patients tested with Fagron Genomics genetic tests across 158+ countries
• +2 more outcomes

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

Partnerships

One partnership is on record.

• Euro OTC PharmaminorGTM or Marketing Partner · 6 May 2026Fagron Genomics partnered with Euro OTC Pharma at the Kongress für Integrative Medizin 2026 in Kos, Greece (May 6-13, 2026). Dr. Gustavo Torres de Souza delivered a lecture on personalized nutrition and hormonal optimization in menopausal women, and Euro OTC Pharma facilitated Fagron Genomics' presence at the congress. This collaboration supports Fagron's educational outreach in integrative medicine.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Color Health: Color Health provides clinical-grade genetic testing through healthcare providers, with a strong focus on hereditary cancer, pharmacogenomics, and preventive health. It is a comparable clinical genetic testing platform competing for similar physician-channel relationships.
• Nutrigenomix: Nutrigenomix offers a clinically validated nutrigenomic test for dietitians and healthcare professionals, analyzing genetic variations related to nutrient metabolism and dietary response. It is the closest direct competitor to Fagron Genomics' NutriGen product in personalized nutrition genetic testing.
• SkinDNA: SkinDNA provides genetic tests that analyze DNA markers linked to skin aging, sun sensitivity, and elasticity to guide personalized skincare and aesthetic treatments. It is a direct competitor to Fagron Genomics' aesthetic and dermatology-focused genetic tests such as AcneTest and TeloTest.
• Prenetics (DNAfit): Prenetics acquired DNAfit, a sport and nutrition genetic testing brand sold through fitness and wellness professionals. Its consumer-facing sport genetics offering directly overlaps with Fagron Genomics' Sport Test and NutriGen.
• TeloYears (Telomere Diagnostics): TeloYears commercialized a direct-to-consumer telomere length test marketed as a biological age indicator. It directly overlaps with Fagron Genomics' TeloTest in telomere-based biological age assessment.

Broad incumbents

• Myriad Genetics: Myriad Genetics is an established molecular diagnostics company specializing in hereditary cancer, pharmacogenomic, and psychiatric genetic testing. It is a broad incumbent in the clinical genetic testing market with significantly larger scale and reimbursement infrastructure.
• 23andMe: 23andMe is the largest direct-to-consumer genetic testing platform, offering health, ancestry, and wellness reports. While not focused on physician-channel pharmacogenomics, it represents a broad incumbent in personalized genetic testing with substantially greater consumer reach.
• GeneDx: GeneDx is a clinical genomics company offering whole exome and genome sequencing for rare disease, hereditary conditions, and pediatric diagnostics. It is a broader incumbent in clinical genetic testing operating at substantially greater scale than Fagron Genomics.

Emerging players

• Genomics plc: Genomics plc uses large-scale genomic and phenotypic data to generate polygenic risk scores for preventive health and drug discovery. It overlaps with Fagron Genomics' positioning in genomic profiling for personalized medicine, particularly in preventive and longevity applications.
• Viome: Viome offers at-home gut microbiome and gene expression tests to generate personalized nutrition and wellness recommendations. It is a partially overlapping player to Fagron Genomics' NutriGen in the personalized nutrition space, differentiated by its microbiome rather than SNP-based approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/FagronGenomicsOfficial

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fagron Genomics